"It is an immense privilege to work alongside world-class scientists in the pursuit of developing life-changing cancer therapeutics."
In 2020, I joined the Oncology Bioinformatics Department with a dual appointment in Discovery Oncology at Genentech. My research revolves around understanding chromatin changes in response to drug perturbations. I am excited about developing computational tools to accelerate drug discovery. My methods (Epiregulon and grnVI) are being used by our oncology programs to inform drug efficacy and understand patient response. Genentech is one of the few places where basic research seamlessly connects with drug discovery.
Prior to Genentech, I trained with Dr. Dane Wittrup at MIT where I identified surface targets important for cancer dissemination. During my postdoctoral training with Dr. Patrick Tan and Dr. Bin Tean Teh at A*STAR Singapore, I discovered how driver mutations fuel tumor growth by co-opting transcription factors and chromatin remodelers.
The tremendous dedication and talent of my trainees have inspired me to be a better scientist myself.
Nature Cell Biology volume 25, pages765–777 (2023).
Cancer Discov (2017) 7 (11): 1284–1305.
The overarching goal of my research is to delineate mechanisms of chromatin changes during drug response. Specifically, I develop computational methods to construct gene regulatory networks and infer transcription factor activity at the single-cell level. I determine mechanisms of action for different drug modalities by identifying interaction partners and/or effectors of chromatin changes. I study chromatin dysregulation driven by cancer mutations and how these mutations impact response to therapeutic agents.